Consensus C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-01 pm EST			5-day change	1st Jan Change
1.600 ^USD	-1.84%		+4.58%	-72.88%

Nov. 20	C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors	CI
Nov. 07	North American Morning Briefing : Higher Bond -2-	DJ

Evolution of the average Target Price on C4 Therapeutics, Inc.

Price target over the last 5 years

History : Analyst Recommendations

1e2d65f38540c4.rTArS-CgxLc-D2qhbmdpp6xSIOJHqmAiri6Eiw-a4sc.ykRvepmSoINGbDDMKwZY7-0Ub6pq2lFm5m3R-WvTt7bdfmQtsvGzwVpOXg~497348055cf4073fa026828499d1e196

Analyst Recommendations on C4 Therapeutics, Inc.

Morgan Stanley Upgrades C4 Therapeutics to Equalweight From Underweight, Cuts Price Target to $1 From $3	Nov. 06	MT
BMO Capital Adjusts Price Target on C4 Therapeutics to $16 From $18, Keeps Outperform Rating	Nov. 03	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $7 From $17, Keeps Buy Rating	Nov. 02	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $17 From $25, Maintains Buy Rating	Aug. 09	MT
UBS Adjusts C4 Therapeutics Price Target to $20 From $22, Maintains Buy Rating	Jul. 21	MT
Evercore ISI Adjusts C4 Therapeutics Price Target to $10 From $20, Maintains Outperform Rating	May. 30	MT
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $3 From $5, Maintains Underweight Rating	May. 12	MT
HC Wainwright Adjusts C4 Therapeutics' Price Target to $25 From $35, Keeps Buy Rating	May. 08	MT
BofA Securities Lowers Price Target on C4 Therapeutics to $5 From $11, Maintains Neutral Rating	Mar. 28	MT
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $5 From $6, Maintains Underweight Rating	Feb. 27	MT
UBS Adjusts C4 Therapeutics Price Target to $22 From $24, Maintains Buy Rating	Feb. 24	MT
JPMorgan Chase Downgrades C4 Therapeutics to Underweight From Neutral, Lowers Price Target to $5 From $15	Feb. 24	MT
Wells Fargo Adjusts Price Target on C4 Therapeutics to $11 From $12, Maintains Equal-Weight Rating	Nov. 08	MT
UBS Adjusts C4 Therapeutics Price Target to $24 From $26, Maintains Buy Rating	Nov. 04	MT
JPMorgan Downgrades C4 Therapeutics to Neutral From Overweight, Adjusts Price Target to $15 From $22	Nov. 04	MT
Morgan Stanley Starts C4 Therapeutics at Underweight With $6 Price Target	2022	MT
Credit Suisse Raises C4 Therapeutics' Price Target to $12 from $10, Keeps Underperform Rating	2022	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy Rating	2022	MT
Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Risk Related to Lead Program Too High	2022	MT
UBS Adjusts C4 Therapeutics Price Target to $26 From $64, Maintains Buy Rating	2022	MT
SVB Leerink Adjusts C4 Therapeutics Price Target to $25 From $40, Maintains Outperform Rating	2022	MT
Stifel Adjusts C4 Therapeutics' Price Target to $15 From $28, Reiterates Hold Rating	2022	MT
BMO Capital Adjusts C4 Therapeutics' Price Target to $20 From $57, Keeps Outperform Rating	2022	MT
BofA Securities Cuts C4 Therapeutics to Neutral From Buy, Price Target to $15 From $46	2022	MT
JPMorgan Starts C4 Therapeutics at Overweight With $43 Price Target	2022	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.600USD

Average target price

16.20USD

Spread / Average Target

+912.50%

High Price Target

84.00USD

Spread / Highest target

+5,150.00%

Low Price Target

1.000USD

Spread / Lowest Target

-37.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering C4 Therapeutics, Inc.

Morgan Stanley
BMO Capital
HC Wainwright
UBS
Evercore ISI
BofA Securities
JPMorgan Chase
Wells Fargo Securities
Credit Suisse
Stifel Nicolaus
SVB Leerink
Brookline Capital Management

Ratings for C4 Therapeutics, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar